TITLE

2011 - Review: Oral drugs for type 2 diabetes, alone or in combination, have different relative benefits and harms for surrogate endpoints

AUTHOR(S)
Domecq, Juan Pablo; Prutsky, Gabriela; Montori, Victor M.
PUB. DATE
August 2011
SOURCE
ACP Journal Club;8/16/2011, Vol. 155 Issue 2, p3
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article reports on a study by W.L. Bennett and colleagues, focusing on the comparative effectiveness and safety of medications for type 2 diabetes. The study shows that oral drugs for type 2 diabetes have different relative benefits and harms for surrogate endpoints. The study also states that clinicians and their patients with diabetes mellitus must find a treatment plan to achieve glycemic control which avoids hypo- and hyperglycemia.
ACCESSION #
65456920

 

Related Articles

  • 2011 - Review: Oral drugs for type 2 diabetes, alone or in combination, have different relative benefits and harms for surrogate endpoints. Domecq, Juan Pablo; Prutsky, Gabriela; Montori, Victor M. // ACP Journal Club;8/16/2011, Vol. 155 Issue 2, p3 

    Question What are the relative effectiveness and safety of oral drugs, alone and in 2-drug combinations, for treatment of type 2 diabetes in adults? Review scope Included studies compared oral drugs, alone or combined with metformin, a thiazolidinedione (TZD), or insulin therapies, for treatment...

  • Review of meta-analyses evaluating surrogate endpoints for overall survival in oncology. Sherrill, Beth; Kaye, James A.; Sandin, Rickard; Cappelleri, Joseph C.; Chen, Connie // OncoTargets & Therapy;2012 Part 2, Vol. 5, p287 

    Overall survival (OS) is the gold standard in measuring the treatment effect of new drug therapies for cancer. However, practical factors may preclude the collection of unconfounded OS data, and surrogate endpoints are often used instead. Meta-analyses have been widely used for the validation of...

  • Using Multiple Targeted Therapies in Oncology: Considerations for Use, and Progress to Date in Breast Cancer. Kelly, Catherine; Buzdar, Aman // Drugs;2013, Vol. 73 Issue 6, p505 

    There has been significant progress in our basic understanding of drugs and targets in the management of breast cancer. Recent breast cancer clinical trials have examined whether combinations of drugs targeting transmembrane receptors or their downstream effectors involved in cell signal...

  • Ezetimibe-Statin Combination Therapy. Nu├čbaumer, Barbara; Glechner, Anna; Kaminski-Hartenthaler, Angela; Mahlknecht, Peter; Gartlehner, Gerald // Deutsches Aerzteblatt International;7/1/2016, Vol. 113 Issue 26, p445 

    Introduction: To date, most clinical comparisons of ezetimibe-statin combination therapy versus statin monotherapy have relied entirely on surrogate variables. In this systematic review, we study the efficacy and safety of ezetimibe-statin combination therapy in comparison to statin monotherapy...

  • Comparative review of drugs for T2D.  // Diabetes Digest;2011, Vol. 10 Issue 3, p176 

    The article discusses a comparative review by W. L. Bennett and colleagues on the harms and benefits of antidiabetes drugs for people with type 2 diabetes.

  • Oral Agents for Type 2 Diabetes: An Update. Kimmel, Bonnie; Inzucchi, Silvio E. // Clinical Diabetes;Spring2005, Vol. 23 Issue 2, p64 

    Discusses research on the use of oral medications in treating type 2 diabetes. Results of clinical trials to determine the effects of available oral agents for type 2 diabetes on patients; Types of oral antihyperglycemic drugs approved by the U.S. Food and Drug Administration; Strategies for...

  • The Role of the U.S. Food and Drug Administration Review Process: Clinical Trial Endpoints in Oncology. McKee, Amy E.; Farrell, Ann T.; Pazdur, Richard; Woodcock, Janet // Oncologist;Mar2010 Supplement, Vol. 15, p13 

    The U.S. Food and Drug Administration grants marketing approval for drug products based on a comprehensive review of safety and efficacy data. The clinical trial endpoints that have been used to support approval in the oncology setting have evolved over the last 30 years commensurate with an...

  • Surrogatendpunkte als Parameter der Nutzenbewertung. Mangiapane, Sandra; Velasco^Garrido, Marcial // GMS Health Technology Assessment;2009, Vol. 5, p1 

    The different actors involved in health system decision-making and regulation have to deal with the question which are valid parameters to assess the health value of health technologies. So called surrogate endpoints represent in the best case preliminary steps in the casual chain leading to the...

  • Endpoints in respiratory diseases. Benedictis, Fernando; Guidi, Roberto; Carraro, Silvia; Baraldi, Eugenio // European Journal of Clinical Pharmacology;May2011 Supplement 1, Vol. 67, p49 

    wide range of outcome measures or endpoints has been used in clinical trials to assess the effects of treatments in paediatric respiratory diseases. This can make it difficult to compare treatment outcomes from different trials and also to understand whether new treatments offer a real clinical...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics